Video

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the differences in survival among studies on iniparib in as a first-, second-, and third-line treatment.

The phase II trial showed a marked difference in survival and disease-free survival, but subsequent studies did not show that with first-line patients. In second- and third-line patients, however, the treatment was effective.

The differences in the trial results have led to discussions regarding tumor heterogeneity and how that heterogeneity might affect a population of patients rather than one particular tumor. In this case, the first-line patients might be different than the second- and third-line patients when it comes to their tumors. Tissue samples are being studied to determine what might be causing this heterogeneity.

Related Videos
Drs Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD